What's Happening?
Biopharmaceutical companies are leveraging HubSpot to manage Key Opinion Leader (KOL) mapping results, integrating data such as KOL tiers, therapeutic areas, influence types, institutional affiliations, and engagement summaries. This approach centralizes
information that various teams, including commercial, medical, and marketing, can access. While HubSpot stores these actionable insights, raw data from claims, publications, payment records, and scientific exchange notes remain in their original systems, with HubSpot linking to them. The process involves matching U.S. KOLs using their 10-digit National Provider Identifier (NPI) to ensure accurate record updates and event attendance tracking. HubSpot's capabilities, particularly with Professional or Enterprise subscriptions, allow for custom properties, association labels, and custom objects to structure KOL data effectively. This includes tracking one-off meetings like congress symposia and dinner programs using marketing events, and managing advisory boards through custom objects.
Why It's Important?
The strategic use of HubSpot for KOL data management is crucial for biopharma companies to maintain a unified and accurate view of influential healthcare professionals. By centralizing KOL information, companies can avoid data silos and inconsistencies that arise when different teams maintain separate records. This streamlined approach enhances collaboration and ensures that all stakeholders operate from the same understanding of each expert's influence and engagement history. The integration of NPIs as a unique identifier is particularly significant for U.S. operations, as it provides a clean match key for updating records and tracking interactions, which is vital for compliance and reporting. Furthermore, the ability to segment and report on KOL data allows medical affairs leaders to identify gaps in coverage and engagement, optimizing outreach strategies and resource allocation. This system helps ensure that engagement with KOLs is both effective and compliant with regulatory standards.
What's Next?
Biopharma companies will continue to refine their HubSpot implementations for KOL management, focusing on maintaining data accuracy and compliance. This includes establishing fixed schedules for refreshing KOL scores from mapping vendors and stamping each record with a 'Last scored' date to ensure data recency. Workflows can be implemented to flag tier changes, prompting medical science liaisons (MSLs) to adjust their engagement strategies accordingly. Future developments may involve further integration with aggregate spend systems to ensure seamless reporting of payments to clinicians, aligning with federal programs like Open Payments. Companies will also likely explore advanced reporting capabilities to gain deeper insights into KOL coverage, engagement recency, and tier movement, enabling more data-driven decision-making in medical affairs and commercial strategies. The ongoing evolution of HubSpot's features, particularly in data management and automation, will likely offer new opportunities for optimizing KOL engagement processes.
Beyond the Headlines
The adoption of platforms like HubSpot for KOL data management highlights a broader trend in the biopharma industry towards digital transformation and data-driven decision-making. Beyond operational efficiencies, this approach carries significant ethical and legal implications, particularly concerning data privacy and compliance. The strict separation of raw mapping inputs, payment records, scientific exchange notes, and patient information from HubSpot underscores the industry's commitment to regulatory adherence and patient confidentiality. The use of property-level access controls and separate owner fields for MSLs and sales representatives reflects an effort to prevent promotional activities from influencing scientific exchanges, maintaining the integrity of medical affairs. This structured data management also fosters greater transparency in interactions with healthcare professionals, which is increasingly scrutinized by regulatory bodies and the public. The continuous refinement of these systems will be essential for navigating the complex landscape of biopharma ethics and compliance.













